(Cyclohexylidene(methoxy)methoxy)trimethylsilane → HCID 69317134, 화합물
반응식
C(O[CH2:4][N:5]1[CH2:10][CH2:9][CH:8]([CH2:11][O:12][C:13]2[C:17]3[C:18]([O:22][CH:23]4[CH2:28][CH2:27][O:26][CH2:25][CH2:24]4)=[CH:19][CH:20]=[CH:21][C:16]=3[O:15][N:14]=2)[CH2:7][CH2:6]1)C.[C:29]1(=[C:35]([O:41][CH3:42])[O:36][Si](C)(C)C)[CH2:34][CH2:33][CH2:32][CH2:31][CH2:30]1.COC(=C1CCOCC1)O[Si](C)(C)C>>[O:26]1[CH2:25][CH2:24][CH:23]([O:22][C:18]2[C:17]3[C:13]([O:12][CH2:11][CH:8]4[CH2:9][CH2:10][N:5]([CH2:4][C:29]5([C:35]([O:41][CH3:42])=[O:36])[CH2:34][CH2:33][CH2:32][CH2:31][CH2:30]5)[CH2:6][CH2:7]4)=[N:14][O:15][C:16]=3[CH:21]=[CH:20][CH:19]=2)[CH2:28][CH2:27]1참가 물질
4
실험 절차
The title compound was prepared according to the procedure described in Step 5 of EXAMPLE 7 using 3-{[1-(ethoxymethyl)piperidin-4-yl]methoxy}-4-(tetrahydro-2H-pyran-4-yloxy)-1,2-benzisoxazole (EXAMPLE 30, Step 1) and [cyclohexylidene(methoxy)methoxy](trimethyl)silane (Tetrahedron 2004, 60, 8957-8966) instead of 4-(benzyloxy)-3-{2-[1-(ethoxymethyl)piperidin-4-yl]ethoxy}-1,2-benzisoxazole and [methoxy(tetrahydro-4H-pyran-4-ylidene)methoxy](trimethyl)silane.